Research Index
Liraglutide Research Index
PSI surfaces 50 peer-reviewed studies on Liraglutide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.
Nielsen GL, Hellström PM, Olesen SS et al.
Scand J Gastroenterol·2026·Human·PubMed →
Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.
Vilsbøll T, Arun Kumar D, Aiello LP et al.
Br J Ophthalmol·2026·Human·PubMed →
Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series.
Mendoza C, Cano R, Burgos L et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.
Shah J, Makwana B, Panchal K et al.
Am J Ophthalmol·2026·Human·PubMed →
A comprehensive analysis of community pharmacists' practices, barriers, and strategies in patient education on Saxenda®: a qualitative study.
Turki AS, Mikhael EM
J Pharm Health Care Sci·2026·Human·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.
Kassab J, Drazner MH, Thibodeau JT
ESC Heart Fail·2026·Human·PubMed →
Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis.
Dong R, Gu L, Li H et al.
Diabetes Metab Syndr Obes·2026·Human·PubMed →
Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Gao W, Cai X, Wang X et al.
Diabetes Metab Syndr Obes·2026·Human·PubMed →
Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.
Zhou G, Liu A, Hu X et al.
Medicine (Baltimore)·2026·Human·Weight Loss, Glycemic Control·PubMed →
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
Galindo RJ, Gudzune KA, Look M et al.
JAMA Netw Open·2026·Human·Weight Loss·PubMed →
Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.
Wolsing SK, Dogan ADA, Juhl CB et al.
Clin Obes·2026·Human·Sleep Apnea, Weight Loss·PubMed →
A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.
Joshi S, Das AK, Khunti K et al.
Diabetes Metab Syndr Obes·2026·Human·PubMed →
Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.
Ciudin A, Sapin H, Fan L et al.
Adv Ther·2026·Human·PubMed →
Impact of Liraglutide on Insulin Clearance in Patients with Type 2 Diabetes Mellitus: Evidence from a Randomized Controlled Trial.
Boelling M, Pu J, Shen J et al.
Diabetes Metab J·2026·Human·PubMed →
Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.
Iglesias P, Nobre EL, Hanzu F et al.
Endocrine·2026·Human·PubMed →
Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.
Gaytan G, Pabon A, Rosario N
J Am Pharm Assoc (2003)·2026·Human·PubMed →
Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.
Cheng H, Jiang X, Zhu X et al.
Obesity (Silver Spring)·2026·Human·Weight Loss, Glycemic Control, Liver Protection·PubMed →
Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.
Xu Y, Huang T, Zhang Y et al.
Circulation·2026·Human·Glycemic Control·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.
Almukhadeb E, Nagshabandi KN, Alshehri N et al.
Int J Dermatol·2026·Human·PubMed →
Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.
Choi WS, Song MK, Seo M et al.
Ther Adv Psychopharmacol·2026·Human·PubMed →
Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.
Van Laren J, Friesleben C, Gershovich O et al.
Diabetes Obes Metab·2026·Human·Glycemic Control·PubMed →
Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study.
Sánchez-García D, Luna-Garza Y, Saavedra-Castillo E et al.
Diabet Med·2026·Human·Cardiovascular Risk·PubMed →
Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.
Bai S, Wei M, Wu Y et al.
BMJ Open·2026·Human·PubMed →
Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use.
Menkü Özdemir FD, Uzun H
Ann Plast Surg·2026·Human·Weight Loss·PubMed →
Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study.
Mai T
Medicine (Baltimore)·2026·Human·Glycemic Control·PubMed →
Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching.
Yuan Z, Jeffcoat CH, Ali SR et al.
PLoS One·2026·Human·Glycemic Control·PubMed →
Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.
Baldassarre MPA, Carrieri F, Coluzzi S et al.
J Diabetes Complications·2026·Human·Glycemic Control·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.
Hsiao FC, Hsu TJ, Hsieh YJ et al.
JAMA Netw Open·2026·Human·Glycemic Control, Cardiovascular Risk·PubMed →
Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.
Ailawadi S, Murphy JE, Storandt MH et al.
Cancers (Basel)·2026·Human·PubMed →
Weekly Liraglutide for the Management of Intractable Polydipsia and Interdialytic Weight Gain in a Patient on Hemodialysis: A Case Report.
Mora-Bravo F, Morales PT, Pincay G et al.
Cureus·2026·Human·PubMed →
Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.
Xu H, Zhang Y
Medicine (Baltimore)·2026·Human·Glycemic Control, Weight Loss·PubMed →
Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
Gutierrez de Piñeres V, Ramirez-Cisneros A, Tamayo-Torres CS et al.
Diabetes Res Clin Pract·2026·Human·Weight Loss, GH Activity, Bone Healing·PubMed →
Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Gonzalez JS, Wen H, Butera NM et al.
Diabetes Care·2026·Human·Glycemic Control·PubMed →
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.
Sheth S, Merola JF, Weber BN et al.
JAMA Dermatol·2026·Animal·PubMed →
Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis.
Abdelrahman RM, Musa TH, Arbab IA et al.
Inquiry·2026·Animal·Glycemic Control, Weight Loss·PubMed →
Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review.
Bihelek N, Burke S, Barry AR
Am J Health Syst Pharm·2026·Animal·PubMed →
Cav3.1 is a neuronal leucine sensor that mediates satiety and weight loss in response to dietary protein.
Tsang AH, Heeley N, Alcaino C et al.
Cell Metab·2026·Animal·PubMed →
The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.
Corcoran E, Kettlety M, Mogul U et al.
Mol Cell Neurosci·2026·Animal·PubMed →
GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction.
Ha J, Lester E, De May H et al.
J Reconstr Microsurg·2026·Animal·PubMed →
Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).
Li J, Liang J, Zhang W et al.
Diabetes Ther·2026·Animal·PubMed →
Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.
Lopez A, Perl L, Cohen-Sela E et al.
Acta Paediatr·2026·Animal·PubMed →
New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development.
Zhao J, Qiu Q, Zhang J et al.
Endocr Metab Immune Disord Drug Targets·2026·Animal·PubMed →
Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.
Aboukaoud M, Hoch B, Weiser M et al.
J Affect Disord·2026·Animal·PubMed →
Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
Engström A, Svanström H, Hviid A et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Insights from changes in NDEV biomarkers of metabolism: Effects of PPARγ and GLP1 receptor agonists on brain metabolism.
Evers A, Watson K, Abbasi F et al.
J Clin Endocrinol Metab·2026·Animal·PubMed →
Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.
Lu Y, Chen J, Guo Y et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.
Gunasekaran P, Inban P, Agrawal A et al.
Dis Mon·2026·Animal·PubMed →
Childhood Obesity, Medications, and Surgeries.
Raghav S, Frishman WH
Cardiol Rev·2026·Animal·PubMed →
Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.
Bu F, Wu R, Ostropolets A et al.
J Am Coll Cardiol·2026·Animal·PubMed →
Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial.
Fang W, Li Z, Xu J et al.
Front Endocrinol (Lausanne)·2025·Human·Glycemic Control, Weight Loss, Anxiety & Mood·PubMed →